2-aminopyrimidine has been researched along with Alzheimer Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alcaro, S; Bagetta, D; Bortolami, M; Carafa, C; Chiarotto, I; Colone, M; Costi, R; De Vita, D; Di Santo, R; Feroci, M; Messore, A; Pandolfi, F; Scipione, L; Stringaro, A | 1 |
| Ahn, HJ; Aso, K; Berk-Rauch, HE; Foley, MA; Kawasaki, M; Nishida, G; Norris, EH; Singh, PK; Strickland, S; Yamasaki, T | 1 |
2 other study(ies) available for 2-aminopyrimidine and Alzheimer Disease
| Article | Year |
|---|---|
New deferiprone derivatives as multi-functional cholinesterase inhibitors: design, synthesis and in vitro evaluation.
Topics: Acetylcholinesterase; Alzheimer Disease; Amines; Amino Acid Sequence; Aminopyridines; Catalytic Domain; Cholinesterase Inhibitors; Coordination Complexes; Deferiprone; Drug Design; Humans; Iron Chelating Agents; Molecular Docking Simulation; Pyrimidines; Structure-Activity Relationship | 2020 |
Aminopyrimidine Class Aggregation Inhibitor Effectively Blocks Aβ-Fibrinogen Interaction and Aβ-Induced Contact System Activation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Drug Design; Fibrinogen; Humans; Peptide Fragments; Protein Aggregates; Protein Aggregation, Pathological; Protein Interaction Maps; Pyrimidines | 2018 |